Pharmaceuticals Middle East

Middle East RNA Interference Therapeutics Market Analysis, 2024–2034

Middle East RNA Interference Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Molecule, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Middle East · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $193.8 Mn Estimated value
Estimate 2025 $234.1 Mn 4.1% of the global market
Projected 2034 $1.28 Bn 447.8% Adds $1.05 Bn over 9 forecast years
CAGR 2025–2034 20.8% Faster than 86% of 180 Pharmaceuticals markets here
Key players 5
  • Middle East is 4.06% of the global market.
  • Among regions, the largest is North America at $3.15 Bn.
  • Fastest growing: Africa at 21.4% a year.
  • Middle East ranks 5th of 6 by size among regions.

Market size projection

Middle East

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.05 Bn total, 2026–2034

Year-by-year market size, 2024–2034
RNA Interference Therapeutics Market market size by year, Middle East
YearMarket sizeChange that yearSince 2025
2024 (estimate) $193.8 Mn — —
2025 (base) $234.1 Mn +$40.3 Mn —
2026 (forecast) $282.8 Mn +$48.7 Mn +20.8%
2027 (forecast) $341.6 Mn +$58.8 Mn +45.9%
2028 (forecast) $412.6 Mn +$71.0 Mn +76.3%
2029 (forecast) $498.4 Mn +$85.8 Mn +112.9%
2030 (forecast) $602.1 Mn +$103.7 Mn +157.2%
2031 (forecast) $727.3 Mn +$125.2 Mn +210.7%
2032 (forecast) $878.6 Mn +$151.3 Mn +275.4%
2033 (forecast) $1.06 Bn +$182.8 Mn +353.5%
2034 (forecast) $1.28 Bn +$220.8 Mn +447.8%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $5.76 Bn
  2. North America $3.15 Bn
  3. US $2.04 Bn
  4. APAC $1.21 Bn
  5. Europe $916.4 Mn
  6. China $461.5 Mn
  7. Canada $445.4 Mn
  8. Japan $320.4 Mn
  9. Latin America $250.8 Mn
  10. Middle East (this report) $234.1 Mn
  11. Germany $212.2 Mn
  12. UK $151.5 Mn
  13. France $149.6 Mn
  14. Brazil $153.7 Mn
  15. Italy $135.7 Mn
  16. Ecuador $123.5 Mn
  17. Saudi Arabia $112.4 Mn
  18. Spain $105.4 Mn
  19. India $110.4 Mn
  20. Africa $86.1 Mn
  21. Mexico $74.7 Mn
  22. Australia $63.3 Mn
  23. Russia $59.8 Mn
  24. New Zealand $59.8 Mn
  25. South Africa $37.5 Mn
  26. UAE $25.3 Mn
  27. Egypt $16.0 Mn
  28. Philippines $14.3 Mn
  29. Malaysia $10.5 Mn
  30. Hong Kong $9.0 Mn
  31. Singapore $8.0 Mn
  32. Thailand $6.5 Mn
  33. Kenya $4.4 Mn

The Middle East RNA Interference Therapeutics Market Analysis Executive Summary

RNA interference therapeutics use small RNA molecules to switch off disease-causing genes, used in rare, heart and liver diseases.

Key segments of the RNA Interference Therapeutics market include molecule (siRNA, Antisense Oligonucleotides and microRNA) and indication (Rare Genetic Diseases, Cardiovascular and Liver Diseases).

Middle East RNA Interference Therapeutics Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the RNA Interference Therapeutics market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the RNA Interference Therapeutics market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the RNA Interference Therapeutics market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for RNA Interference Therapeutics Market in Middle East

The RNA Interference Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for RNA Interference Therapeutics Market in Middle East

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for RNA Interference Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Middle East.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in RNA Interference Therapeutics right now, from free public sources.

Clinical trials

1 active trial in UAE, Saudi Arabia, Yemen, Jordan, Lebanon, Qatar, Syria, Palestine and Iraq

Recruiting, about to start, or running now. Counted across the 9 countries we report on in Middle East.

Top trial sponsors (worldwide)

  1. Alnylam Pharmaceuticals 10 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Regeneron Pharmaceuticals 7 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Novartis AG 5 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Ribocure Pharmaceuticals AB 3 active trials on ClinicalTrials.gov (opens in a new tab)
  5. ADARx Pharmaceuticals, Inc. 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 28 papers since 2021 (worldwide)

  1. Deep and durable lipoprotein(a) lowering: Kylo-11 advances RNA interference therapeutics. Lancet (London, England), 2026
  2. The Biochemical and Genetic Architecture of Geographic Atrophy: The Role of the FHL-1/CFH Axis and the Paradigm of RNA Interference Therapeutics. Biomedicines, 2026
  3. Gene delivery for cerebral neurodegenerative disorders: Current advancements and limitations. Molecular therapy : the journal of the American Society of Gene Therapy, 2026
  4. Response to the letter to the editor regarding "Use of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy". Journal of the Formosan Medical Association = Taiwan yi zhi, 2026
  5. Comment on "Use of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy". Journal of the Formosan Medical Association = Taiwan yi zhi, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

RNA Interference Therapeutics in context

Questions, answered with public data

How many clinical trials on RNA Interference Therapeutics are running in Middle East?
1 study is recruiting, active or about to start in Middle East, counted across the 9 countries we report on there.[1]
How much research is published on RNA Interference Therapeutics?
PubMed lists 28 papers added since January 2021 that match this market, worldwide.[2]

[1] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Middle East. Retrieved 12 Nov 2026.

[2] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about RNA Interference Therapeutics in Middle East? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Patient Support Programmes: Helping Patients Stay on TreatmentWHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient… Biologic Safety Testing: The Quiet Backbone of Drug MakingEvery vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches… Cell-Based Immunotherapy: Promise and PriceThe first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Middle East

See all
Same topic, other categories

Related on biologics and biosimilars and genomics

See the topic